TY - JOUR
T1 - The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis
T2 - A double-blind, randomized, placebo-controlled study
AU - Mansouri, Ava
AU - Hadjibabaie, Molouk
AU - Iravani, Masoud
AU - Shamshiri, Ahmad Reza
AU - Hayatshahi, Alireza
AU - Javadi, Mohammad Reza
AU - Khoee, Seid Hamid
AU - Alimoghaddam, Kamran
AU - Ghavamzadeh, Ardeshir
N1 - Enter your email address below. If your address has been previously registered, you will receive an email with instructions on how to reset your password. If you don't receive an email, you should register as a new user
PY - 2012/3
Y1 - 2012/3
N2 - The purpose of this study was to evaluate the effect of oral zinc sulfate in the prevention of chemotherapy-induced mucositis in patients undergoing hematopoietic stem-cell transplantation (HSCT). This study was a double-blind, randomized, placebo-controlled design, with 60 patients undergoing HSCT, divided proportionally in experimental group who received zinc sulfate, and in placebo group. They all had received high-dose chemotherapy conditioning regimen for allogenic transplantation. Oral mucositis assessed was based on World Health Organization (WHO) oral mucositis scale. There were no significant differences in the development of mucositis between the two groups. Severity of mucositis was not significantly different between the two groups either. The same result was obtained regarding the duration of mucositis. Zinc sulfate did not show any significant adverse effects in experimental group. In conclusion, Zinc sulfate did not have any clinical benefits in prevention or reduction of severity, and duration of high-dose chemotherapy-induced mucositis in patients undergoing HSCT.
AB - The purpose of this study was to evaluate the effect of oral zinc sulfate in the prevention of chemotherapy-induced mucositis in patients undergoing hematopoietic stem-cell transplantation (HSCT). This study was a double-blind, randomized, placebo-controlled design, with 60 patients undergoing HSCT, divided proportionally in experimental group who received zinc sulfate, and in placebo group. They all had received high-dose chemotherapy conditioning regimen for allogenic transplantation. Oral mucositis assessed was based on World Health Organization (WHO) oral mucositis scale. There were no significant differences in the development of mucositis between the two groups. Severity of mucositis was not significantly different between the two groups either. The same result was obtained regarding the duration of mucositis. Zinc sulfate did not show any significant adverse effects in experimental group. In conclusion, Zinc sulfate did not have any clinical benefits in prevention or reduction of severity, and duration of high-dose chemotherapy-induced mucositis in patients undergoing HSCT.
KW - High-dose chemotherapy
KW - Mucositis
KW - Zinc sulfate
UR - https://www.scopus.com/pages/publications/84858150708
UR - https://www.scopus.com/pages/publications/84858150708#tab=citedBy
U2 - 10.1002/hon.999
DO - 10.1002/hon.999
M3 - Article
C2 - 21692101
SN - 0278-0232
VL - 30
SP - 22
EP - 26
JO - Hematological Oncology
JF - Hematological Oncology
IS - 1
ER -